secwatch.observer — SEC 8-K summary
======================================

Issuer:     Instil Bio, Inc. (TIL)
CIK:        0001789769
Form:       8-K
Filed at:   2025-05-13T23:59:59+00:00
Accession:  0001789769-25-000050
Event type: earnings
Sentiment:  negative
Materiality: 0.65
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Instil Bio Q1 net loss $4.32/share; restructuring charges $16.1M; cash $111.8M
------------------------------------------------------------------------------

- Net loss per share $4.32 (GAAP) vs $3.74 YoY; non-GAAP $1.32 vs $2.39.
- Cash and investments $111.8M, down from $115.1M at Dec 31, 2024; runway beyond 2026.
- Restructuring & impairment charges $16.1M vs $4.3M YoY; R&D $5.4M, G&A $9.1M.
- AXN-2510/IMM2510 China trial ongoing; initial 1L NSCLC data expected 2H 2025.
- U.S. clinical study of AXN-2510/IMM2510 in 1L NSCLC anticipated before end 2025.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1789769/000178976925000050/0001789769-25-000050-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1789769/000178976925000050/til-20250513.htm
  HTML page:      https://secwatch.observer/filing/0001789769-25-000050

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer